Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 23, 2006, Pages 3780-3788

  Hsu, Yu Chen ^a   Fu, Hsiao Hui ^a   Jeng, Yung Ming ^a   Lee, Po Huang ^a   Yang, Shiaw Der ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROLINE DIRECTED PROTEIN KINASE; PROLINE DIRECTED PROTEIN KINASE F A; UNCLASSIFIED DRUG; FOCAL ADHESION KINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ANALYSIS OF VARIANCE; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; LIVER TUMOR; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747365877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.7499     Document Type: Article

References (50)

1. Thomas MB, Zhu AX: Hepatocellular carcinoma: The need for progress. J Clin Oncol 23:2892-2899, 2005
2. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40:225-235, 2005
3. Bruix J, Boix L, Sala M, et al: Focus on hepatocellular carcinoma. Cancer Cell 5:215-219, 2004
4. Cusnir M, Patt YZ: Novel systemic therapy options for hepatocellular carcinoma. Cancer J 10: 97-103, 2004
5. Ganne-Carrie N, Trinchet JC: Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 16:275-281, 2004
6. Van Deusen MA, Abdalla EK, Vauthey JN, et al: Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 5:377-383, 2005
7. Suriawinata A, Xu R: An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 24:77-88, 2004
8. Qin LX, Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: A review of the literature. J Cancer Res Clin Oncol 130:497-513, 2004
9. Chen PJ, Chen DS: Hepatitis B virus infection and hepatocellular carcinoma: Molecular genetics and clinical perspectives. Semin Liver Dis 19:253-262, 1999
10. Bergsland EK: Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol 28:521-531, 2001
11. Yang SD, Vandenheede JR. Goris J, et al: ATP Mg-dependent protein phosphatase from rabbit skeletal muscle: I, Purification of the enzyme and its regulation by the interaction with an activating protein factor J Biol Chem 255:11759-11767, 1980
12. Vandenheede JR, Yang SD, Goris J, et al: ATP Mg-dependent protein phosphatase from rabbit skeletal muscle: II, Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity J Biol Chem 255:11768-11774, 1980
13. A) as a myelin basic protein kinase in the brain. J Biol Chem 261:11786-11791, 1986
14. 404-Pro that are abnormally phosphorylated in Alzheimer's disease brain. J Neurochem 61:1742-1747, 1993
15. A after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain. J Neurochem 63:1416-1425, 1994
16. 97-Pro in brain myelin basic protein: Evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequence motifs. J Neurochem 62:1596-1603, 1994
17. 666 in neurofilament. J Neurochem 64:1848-1854, 1995
18. A). Adv Prot Phosphatase 6:133-157, 1991
19. A). J Chin Biochem Soc 23:123-134, 1994
20. A expression inhibits the growth of human chronic myeloid leukaemia cells. Br J Cancer 82:1480-1484, 2000
21. A expression potentiates erythroid differentiation of human myeloid leukemia cells. Cancer 89:1004-1011, 2000
22. A correlates with human thyroid tumor cell dedifferentiation. J Cell Biochem 58:474-480, 1995
23. A (a proline-directed kinase and a regulator of protooncogenes) with human cervical carcinoma dedifferentiation/progression. J Cell Biochem 59:143-150, 1995
24. A (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression. J Cell Biochem 61:238-245, 1996
25. A enhances chemosensitivity in human prostate cancer cells. Clin Cancer Res 6:1024-1030, 2000
26. A potentiates apoptotic induction and greatly enhances chemosensitivity in human acute lymphoblastic leukemia cells. Cancer 92:1753-1758, 2001
27. A systemically inhibits the growth of human acute leukemia cells. Int J Cancer 91:650-653, 2001
28. A with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer 95:1840-1847, 2002
29. A with chemoresistance, invasion, and recurrence in patients with bladder carcinoma. Cancer 95:775-783, 2002
30. A inhibits the malignant growth of human pancreatic ductal adenocarcinoma. Anticancer Res 24:1489-1494, 2004
31. A as a potential target for diagnosis and therapy of human cancers. Curr Cancer Drug Targets 4:591-596, 2004
32. Edmonson HA, Steiner PE: Primary carcinoma of the liver: A study of 100 among 489,000 necropsies. Cancer (Phila) 7:462-503, 1954
33. Hsu HC, Jeng YM, Mao TL, et al: Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 157:763-770, 2000
34. Liu SH, Lin CY, Peng SY, et al: Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 160:1831-1837, 2002
35. Jeng YM, Peng SY, Lin CY, et al: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065-2071, 2004
36. Reichlin M: Use of glutaraldehyde as a coupling agent for proteins and peptides. Methods Enzymol 70:159-165, 1980
37. The Liver Cancer Study Group of Japan: Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74:2772-2780, 1994
38. Fong Y, Sun RL, Jarnagin W, et al: An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229:790-800, 1999
39. Jaeck D, Bachellier P, Oussoultzoglou E, et al: Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: An overview. Liver Transpl 10:S58-S63, 2004
40. Poon RT, Fan ST: Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome. Liver Transpl 10:S39-S45, 2004
41. Schoniger-Hekele M, Hanel S, Wrba F, et al: Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 25:62-69, 2005
42. Yamamoto S, Tomita Y, Nakamori S, et al: Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol 21:447-452, 2003
43. Chen WT, Chau GY, Lui WY, et al: Recurrent hepatocellular carcinoma after hepatic resection: Prognostic factors and long-term outcome. Eur J Surg Oncol 30:414-420, 2004
44. Lin SM, Lin CJ, Hsu CW, et al: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100:376-382, 2004
45. Hu TH, Huang CC, Liu LF, et al: Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98:1444-1456, 2003
46. Lee WC, Jeng LB, Chen MF: Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg 89:311-316, 2002
47. King KL, Li AF, Chau GY, et al: Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 88:2464-2470, 2000
48. Varela M, Sala M, Llovet JM, et al: Treatment of hepatocellular carcinoma: Is there an optimal strategy? Cancer Treat Rev 29:99-104, 2003
49. Qin LX, Tang ZY: The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 8:193-199, 2002
50. Poon RT, Fan ST, Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10-24, 2000